mNos2 deletion and human NOS2 replacement in Alzheimer disease models.

Journal Article (Journal Article)

Understanding the pathophysiologic mechanisms underlying Alzheimer disease relies on knowledge of disease onset and the sequence of development of brain pathologies. We present a comprehensive analysis of early and progressive changes in a mouse model that demonstrates a full spectrum of characteristic Alzheimer disease-like pathologies. This model demonstrates an altered immune redox state reminiscent of the human disease and capitalizes on data indicating critical differences between human and mouse immune responses, particularly in nitric oxide levels produced by immune activation of the NOS2 gene. Using the APPSwDI(+)/(+)mNos2(-/-) (CVN-AD) mouse strain, we show a sequence of pathologic events leading to neurodegeneration,which include pathologically hyperphosphorylated tau in the perforant pathway at 6 weeks of age progressing to insoluble tau, early appearance of β-amyloid peptides in perivascular deposits around blood vessels in brain regions known to be vulnerable to Alzheimer disease, and progression to damage and overt loss in select vulnerable neuronal populations in these regions. The role of species differences between hNOS2 and mNos2 was supported by generating mice in which the human NOS2 gene replaced mNos2. When crossed with CVN-AD mice, pathologic characteristics of this new strain (APPSwDI(+)/(-)/HuNOS2(tg+)/(+)/mNos2(-/-)) mimicked the pathologic phenotypes found in the CVN-AD strain.

Full Text

Duke Authors

Cited Authors

  • Colton, CA; Wilson, JG; Everhart, A; Wilcock, DM; Puoliväli, J; Heikkinen, T; Oksman, J; Jääskeläinen, O; Lehtimäki, K; Laitinen, T; Vartiainen, N; Vitek, MP

Published Date

  • August 2014

Published In

Volume / Issue

  • 73 / 8

Start / End Page

  • 752 - 769

PubMed ID

  • 25003233

Pubmed Central ID

  • PMC4131941

Electronic International Standard Serial Number (EISSN)

  • 1554-6578

Digital Object Identifier (DOI)

  • 10.1097/NEN.0000000000000094


  • eng

Conference Location

  • England